Navigation Links
Principles of CAR T Cell Therapy and the Pathway to Regulatory Approval, Upcoming Webinar Hosted by Xtalks
Date:5/31/2019

For many years, the primary forms of cancer treatment have been chemotherapy, radiation and surgery, but the toughest forms of cancer demand breakthrough therapies. Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor T (CAR T) cell therapy, which combines a patient’s own T cells with engineered T cell receptors known as “CARs”. The CAR enables the final product to produce chemicals in the hopes that the “enhanced” product or cells will bind to the cancer cells and kill them.

The industry has seen successes in using CAR T therapy in several blood cancers, including acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma. Some of these unique therapies have already been cleared by the US Food and Drug Administration (FDA), but the pathway to the clinic comes with several challenges.

Join Brian D. Marks, BSc, DC, Senior Director, Project Delivery, Oncology at Premier Research and Ashley Jones, MSc, Project Lead, Project Management, Oncology at Premier Research in a live webinar on Tuesday, June 18, 2019 at 11am EDT (4pm BST/UK) to learn about:

  •     Principles of CAR-T cell therapy
  •     FDA-approved CAR-T cell therapies
  •     Operational and clinical pathways that bring CAR-T cell therapies to patients
  •     Challenges with clinical application

For more information or to register for the complimentary session, visit Principles of CAR T Cell Therapy and the Pathway to Regulatory Approval.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Candice Tang
Tel: +1 (416) 977-6555 ext 400
Email: ctang@xtalks.com

Read the full story at https://www.prweb.com/releases/principles_of_car_t_cell_therapy_and_the_pathway_to_regulatory_approval_upcoming_webinar_hosted_by_xtalks/prweb16340590.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Investors Applaud Amgen and Novartis for Support of Investor Principles on Biosimilars, Alternatives to Higher Cost Drugs
2. Chemical Publishing Company to Release New Title Boiler Water Treatment Principles and Practice: Charts and Notes for Field Use
3. VetStem Biopharma Shares the Story of Atlas Who Was Successfully Treated with VetStem Cell Therapy by Dr. Colter Negranti
4. VetStem Biopharma Shares the Success Story of Frank who was Treated with VetStem Cell Therapy by Pain Management Specialist Dr. Jamie Gaynor
5. VetStem Biopharma Shares the Story of Sonny Bar Lisa Who Was Successfully Treated With VetStem Cell Therapy
6. ASGCT Members Elect Five New Directors from CHOP, UMass, Advanced Therapy Partners, bluebird bio, and Vanderbilt University
7. VetStem Regenerative Cell Therapy Helps Arthritic Sun Bear at the World-Famous San Diego Zoo
8. VetStem Biopharma is Pleased to Share the Success Story of Bogey Who Was Treated with VetStem Cell Therapy by Dr. Ava DeCozio
9. Sheba Medical Center to Collaborate with Lonza Pharma on State-of-the-Art "Cocoon" Platform to Aid Cancer Patients' Access to Life-Saving CAR-T Immunotherapy Treatments
10. VetStem Biopharma Shares the Story of San Fransisko Who Advanced in His Dressage Career After Being Treated with VetStem Cell Therapy
11. AskBio Announces First Patient Dosed with Gene Therapy in Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2020)... ... June 25, 2020 , ... Lumeda Inc. ... cancer, today announced the company has entered a license agreement with Roswell Park ... Lumeda globally exclusive rights to Roswell Park intellectual property surrounding a novel medical ...
(Date:6/23/2020)... ... 23, 2020 , ... Kerafast Inc. , developers of ... the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, ... SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) ...
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... ... now offering an Amniosomes special offer. This includes buy three, get the fourth ... call (888) 568-6909. , Amniotic derived exosomes, known as exosomes, have been a ...
(Date:6/23/2020)... ... June 23, 2020 , ... Nobilis Therapeutics, a ... it has filed an Investigational New Drug application (IND) with the U.S. Food ... lead drug candidate NBTX-001 in patients with panic disorder (PD). , "Adding a ...
Breaking Biology Technology:
(Date:7/10/2020)... ... , ... Today CJ BIO announced the first in a series of Food ... phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range ... 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in ... Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software and software-driven clinical data services that accelerate drug development, is collaborating with ... an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first ...
Breaking Biology News(10 mins):